The association between renal function and BMD response to bisphosphonate treatment: Real-world cohort study using linked national registers.
BACKGROUND
Management of osteoporosis given reduced renal function is one of the largest challenges in the bone clinic.


OBJECTIVES
Identify the cut-off for renal function below which there would be no overall BMD benefit associated with bisphosphonate use. Track safety outcomes resulting in hospital encounters.


METHODS
Population-based, observational register-linked study of BMD trajectories in adults from the island of Funen (pop 465,000) as a function of estimated creatinine clearance (CKD-epi), treatment and adherence to oBP. One laboratory performed all the biochemical analyses for the area while all DXA scans were in a central facility. For inclusion, patients were required to have both a DXA scan and an eGFR measurement (CKD-EPI) within 1 year prior to their study index date. Medication Possession Ratio (MPR) was calculated from national data.


RESULTS
Out of 6176 incident BP users, 1789 had eGFR and DXA measurements at appropriate timepoints for the planned analysis, while this was the case for 3908 of 29,336 non-users. Users of oBPs exhibited progressively smaller gains in BMD with decreasing renal function. However, for CKD stage 3A and better, the annual change in BMD was significantly more positive than in the non-user group at similar levels of renal function. In non-users, the average annual change in BMD was negative but largely unaffected by renal function down to stage 3B. There were no new cases of acute renal injury, glomerulonephritis or dialysis. The rate of new kidney transplantation was zero in non-users and 0.26 per 1000 PY in the BP user population. Hypocalcaemia encounters did not differ significantly from that seen in non-users.


CONCLUSIONS
The BMD changes observed in real-world users of oBP in this population based single-clinic are consistent with those observed in the original RCTs of alendronate. We noted a gradual decrease in the absolute gains in BMD in oBP users with decreasing renal function though there was no significant interaction - largely explained by low numbers of treated patients with poor renal function - between CKD stage and adherence driven BMD change. There were no cases of acute renal injury resulting in hospital encounters. More data is needed on the efficacy and safety of bisphosphonates in CKD stage 3B to 5 and prescribers should reconsider the low use of DXA in patients with renal function impairment now that a wider range of treatment options are available.
['Abrahamsen|Bo|B|', 'Ernst|Martin T|MT|', 'Smith|Christopher D|CD|', 'Nybo|Mads|M|', 'Rubin|Katrine Hass|KH|', 'Prieto-Alhambra|Daniel|D|', 'Hermann|Anne Pernille|AP|']
D015502:Absorptiometry, Photon D000328:Adult D015519:Bone Density D015331:Cohort Studies D004164:Diphosphonates D006801:Humans D010024:Osteoporosis
Bisphosphonates Osteoporosis Bone mineral density Epidemiology Renal disease